Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Muratovska, Chaoming Zhou, Shujie He, P. Goodyer, M. Eccles (2003)
Paired-Box genes are frequently expressed in cancer and often required for cancer cell survivalOncogene, 22
N. Chi, J. Epstein (2002)
Getting your Pax straight: Pax proteins in development and disease.Trends in genetics : TIG, 18 1
A. Laury, R. Perets, H. Piao, J. Krane, J. Barletta, C. French, L. Chirieac, R. Lis, M. Loda, J. Hornick, R. Drapkin, M. Hirsch (2011)
A Comprehensive Analysis of PAX8 Expression in Human Epithelial TumorsThe American Journal of Surgical Pathology, 35
P. Sanyanusin, J. Norrish, T. Ward, A. Nebel, L. McNoe, M. Eccles (1996)
Genomic structure of the human PAX2 gene.Genomics, 35 1
J. Rabban, S. McAlhany, M. Lerwill, J. Grenert, C. Zaloudek (2010)
PAX2 Distinguishes Benign Mesonephric and Mullerian Glandular Lesions of the Cervix From Endocervical Adenocarcinoma, Including Minimal Deviation AdenocarcinomaThe American Journal of Surgical Pathology, 34
Q. Zhai, A. Ozcan, Candice Hamilton, S. Shen, D. Coffey, B. Krishnan, L. Truong (2010)
PAX-2 Expression in Non-neoplastic, Primary Neoplastic, and Metastatic Neoplastic Tissue: A Comprehensive Immunohistochemical StudyApplied Immunohistochemistry & Molecular Morphology, 18
G. Silberstein, G. Dressler, Katharine Horn (2002)
Expression of the PAX2 oncogene in human breast cancer and its role in progesterone-dependent mammary growthOncogene, 21
(2003)
World Health Organization classification of tumors pathology and genetics: Tumors of the Breast and Female Genital Organs. Lyon: IARC
N. Ordóñez (1998)
Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 11 10
E. Robson, Shujie He, M. Eccles (2006)
A PANorama of PAX genes in cancer and developmentNature Reviews Cancer, 6
V. Gotzos, P. Vogt, M. Celio (1996)
The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type.Pathology, research and practice, 192 2
M. Chivukula, D. Dabbs, S. O'Connor, R. Bhargava (2009)
PAX 2: A Novel Müllerian Marker for Serous Papillary Carcinomas to Differentiate From Micropapillary Breast CarcinomaInternational Journal of Gynecological Pathology, 28
Y. Takeshima, V. Amatya, K. Kushitani, K. Inai (2008)
A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.American journal of clinical pathology, 130 5
A. Mansouri, Guy Goudreau, Peter Gruss (1999)
Pax genes and their role in organogenesis.Cancer research, 59 7 Suppl
A. Laury, J. Hornick, R. Perets, J. Krane, J. Corson, R. Drapkin, M. Hirsch (2010)
PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant MesotheliomaThe American Journal of Surgical Pathology, 34
J. Kreidberg, H. Sariola, J. Loring, M. Maeda, J. Pelletier, D. Housman, R. Jaenisch (1993)
WT-1 is required for early kidney developmentCell, 74
C. Tung, S. Mok, Y. Tsang, Z. Zu, Huijuan Song, Jinsong Liu, M. Deavers, A. Malpica, J. Wolf, K. Lu, D. Gershenson, K. Wong (2009)
PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous CarcinomasModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 22
R. Attanoos, R. Webb, S. Dojcinov, A. Gibbs (2002)
Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneumHistopathology, 40
S. Kerrigan, R. Turnnir, P. Clement, R. Young, A. Churg (2002)
Diffuse malignant epithelial mesotheliomas of the peritoneum in womenCancer, 94
G. Tong, L. Chiriboga, D. Hamele-Bena, A. Borczuk (2007)
Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?Modern Pathology, 20
A. Abutaily, B. Addis, W. Roche (2002)
Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodiesJournal of Clinical Pathology, 55
C. Doglioni, Angelo Dei, L. Laurino, P. Iuzzolino, C. Chiarelli, M. Celio, G. Viale (1996)
Calretinin: a novel immunocytochemical marker for mesothelioma.The American journal of surgical pathology, 20 9
M. Hirose (1999)
The role of Wilms' tumor genes.The journal of medical investigation : JMI, 46 3-4
W. Wiseman, C. Michael, M. Roh (2011)
Diagnostic utility of PAX8 and PAX2 immunohistochemistry in the identification of metastatic Müllerian carcinoma in effusionsDiagnostic Cytopathology, 39
N. Ordóñez (2006)
Value of Immunohistochemistry in Distinguishing Peritoneal Mesothelioma From Serous Carcinoma of the Ovary and Peritoneum: A Review and UpdateAdvances in Anatomic Pathology, 13
N. Ordóñez (2006)
The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative studyModern Pathology, 19
M. Eccles, Shujie He, M. Legge, R. Kumar, J. Fox, Chaoming Zhou, M. French, Robert Tsai (2002)
PAX genes in development and disease: the role of PAX2 in urogenital tract development.The International journal of developmental biology, 46 4
K. Sainio, P. Hellstedt, J. Kreidberg, L. Saxén, H. Sariola (1997)
Differential regulation of two sets of mesonephric tubules by WT-1.Development, 124 7
N. Ordóñez (1998)
Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas.The American journal of surgical pathology, 22 10
Downloaded from http://journals.lww.com/appliedimmunohist by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/10/2020 RESEARCH ARTICLE Is PAX2 a Reliable Marker in Differentiating Diffuse Malignant Mesotheliomas of Peritoneum From Serous Carcinomas of Mu¨llerian Origin? Faye F. Gao, MD, PhD, Alyssa M. Krasinskas, MD, and Mamatha Chivukula, MD, FCAP, FASCP peritoneal carcinomatosis or extraovarian carcinoma. In Abstract: Diffuse peritoneal malignant mesotheliomas (DPMM) contrast, serous carcinomas (SC) are an aggressive type of are often disseminated in the peritoneal cavity as multiple cancers that arise from various organs of mullerian lineage nodules including localized masses in the ovaries that are including ovaries, endometrium, fallopian tubes, perito- clinically and histologically similar to serous adenocarcinomas neum, and cervix. Primary peritoneal serous carcinoma of mullerian origin. It is imperative to differentiate these tumors (PPSC) and ovarian serous carcinoma (OSC) are 2 given their diverse responses to chemotherapy and/or radio- histologically similar SC of mullerian origin that have the therapy. PAX2 gene was recently demonstrated in benign propensity to spread to the serosal surface. DPMM may epithelial cells of the female genital tract and in serous also histologically show a carcinomatous growth pattern carcinomas (SC) of mu¨ llerian origin. The aim of our study and is easily confused with PPSC. Although the criteria
Applied Immunohistochemistry & Molecular Morphology – Wolters Kluwer Health
Published: May 1, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.